Wang-LysoLab

🧬Does this change the overall safety assessment of AAV gene therapy? After treating over 6,000 patients with AAV gene therapy without evidence of major long-term toxic effects, now the first published case of human oncogenesis linked to AAV integration has been documented: A 5-year-old boy with severe mucopolysaccharidosis type I (MPS I, Hurler syndrome) developed a neuroepithelial tumor four years after intracisternal magna administration of AAV9 gene therapy. 🔬 The molecular detective work is fascinating: Clonal integration of rearranged AAV vector elements into the PLAG1 gene, creating a chimeric AAV-PLAG1 transcript that drove tumor development. The integrated AAV DNA included duplicated enhancer-promoter sequences that upregulated PLAG1 expression 298-fold compared to other CNS tumors ✅ The tumor was successfully resected, and the patient maintains advanced cognitive function. ⚖️ Does this change the overall safety assessment? Not fundamentally, but it sharpens our focus. While AAV vectors predominantly persist as episomal concatemers, rare genomic integration has been known from neonatal murine models and liver biopsies in gene therapy patients. 👉 This case should translate into more stringent pharmacovigilance, with systematic long-term follow-up and tumor surveillance embedded into all AAV-based gene therapy programs. 🎯 Context is everything: The risk-benefit calculation varies dramatically by disease, vector design, dose, and delivery route. This case involved: - High vector concentrations (intracisternal magna delivery) - Ubiquitous promoter elements (necessary for lysosomal storage disease) - Possible host factors (prior HSCT) For conditions like haemophilia treated with lower systemic administration and liver-specific promoters, the profile differs markedly from CNS-directed therapy for MPS I, which requires ubiquitous promoters and high CNS transduction. #genetherapy #haemophilia @NEJM Rebecca Ahrens-Nicklas @DrSamelsonJones @LindseyAGeorge nejm.org/doi/full/10.1056/NE…